formyl-L-Met-Aib-L-Phe-OMe

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: formyl-L-Met-Aib-L-Phe-OMe
• 英文别名: methyl (2S)-2-[[2-[[(2S)-2-formamido-4-methylsulfanylbutanoyl]amino]-2-methylpropanoyl]amino]-3-phenylpropanoate
• 化学式: C₂₀H₂₉N₃O₅S
• 分子量: 423.5
• InChiKey: GHILYXCSQZCOSX-HOTGVXAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  29
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  139
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'INFECTIONS FONGIQUES
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2015164289A1

  公开（公告）日：2015-10-29

  Compositions and methods for the treatment of fungal infections including compounds containing a chemotaxis receptor ligand moiety and a polyene antifungal agent moiety are disclosed. In particular, compounds containing a polyene antifungal agent and a formyl peptide receptor ligand can be used in the treatment of fungal infections caused by a fungus of the genus Aspergillus or Candida.

  揭示了用于治疗真菌感染的化合物和方法，包括含有趋化受体配体基团和聚烯抗真菌剂基团的化合物。具体来说，含有聚烯抗真菌剂和甲酰肽受体配体的化合物可用于治疗由曲霉属或白念珠菌属真菌引起的真菌感染。
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS
  申请人：CIDARA THERAPEUTICS, INC

  公开号：US20160213742A1

  公开（公告）日：2016-07-28

  Compositions and methods for the treatment of fungal infections including compounds containing a pathogen pattern recognition receptor ligand and a β 1,3-glucan synthase inhibitor are disclosed. In particular, compounds containing a lipopeptide moiety and a formyl peptide receptor ligand can be used in the treatment of fungal infections caused by a fungus of the genus Aspergillus or Candida.

  本发明涉及用于治疗真菌感染的组合物和方法，其中包括含有病原体模式识别受体配体和β 1,3-葡聚糖合成酶抑制剂的化合物。特别地，含有脂肽基团和甲酰肽受体配体的化合物可用于治疗由曲霉属或白色念珠菌属真菌引起的真菌感染。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT D'INFECTIONS FONGIQUES
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2015035102A2

  公开（公告）日：2015-03-12

  Compositions and methods for the treatment of fungal infections including compounds containing a pathogen pattern recognition receptor ligand and a β 1,3-glucan synthase inhibitor are disclosed. In particular, compounds containing a lipopeptide moiety and a formyl peptide receptor ligand can be used in the treatment of fungal infections caused by a fungus of the genus Aspergillus or Candida.